A.R.R.O.W.2: once- vs twice-weekly carfilzomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma.

Efficacy ORR was 82.5% (95% CI, 76.9-87.2) in the once-weekly KRd56 group vs 86.3% (95% CI, 81.1-90.5) in the twice-weekly KRd27 group (risk ratio [once-weekly KRd56/twice-weekly KRd27] = 0.954 [95% CI, 0.882-1.032]; P = .0666; Table 2 ), which did not reach statistical significance for noninferiority at the prespecified alpha threshold of P ≤ .025, 1-sided.

also in 17,681 other papers